In this work, using cancer cell lines from different origin and known to be resistant to recombinant TRAIL, we demonstrated that pharmacologic inhibition of ERK5 is an effective strategy to improve TRAIL cytotoxicity, by stabilizing TP53IP2 protein levels. This evidence concerns the gene MAPK7 and cancer.